Singapore Pharmaceuticals and Healthcare Report Q2 2016

106 pages report Published in
Pharmaceuticals
Publisher: Business Monitor International

arrowFor This Report

BMI View: Non-communicable disease will continue to dominate Singapore’s epidemiological profile,
creating strong commercial opportunities for medicines addressing these illnesses. Companies seeking to
benefit from these revenue earning prospects will have to compete with the population’s ongoing use of
alternative treatments as a supplement to conventional medicine.
Headline Expenditure Projections
? Pharmaceuticals: SGD1.10bn (USD798mn) in 2015 to SGD1.15bn (USD790mn) by 2016; +5.1% in
local currency terms and -0.9% in USD terms.
? Healthcare: SGD19.67bn (USD14.31bn) in 2015 to SGD21.15bn (USD14.50bn) by 2016; +7.5% in
local currency terms and 1.3% in USD terms.

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2012-2020) 12
Healthcare Market Forecast 13
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020) 15
Prescription Drug Market Forecast 16
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 17
Patented Drug Market Forecast 18
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 19
Generic Drug Market Forecast 20
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 22
OTC Medicine Market Forecast 23
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2012-2020) 24
Pharmaceutical Trade Forecast 25
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2014-2020) 27
Industry Risk/Reward Index 28
Asia Pacific Risk/Reward Index 28
Singapore Risk/Reward Index 34
Rewards 34
Risks 34
Regulatory Review 35
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA 37
Intellectual Property Issues 38
Pricing And Reimbursement Regime 39
Market Overview 44
Healthcare Sector 44
Table: Health Funding Sources In Singapore (SGDmn) 49
Table: Healthcare Resources (Singapore 2010-2015) 53
Table: Healthcare Activity (Singapore 2010-2015) 53
Table: Healthcare Personnel (Singapore 2010-2015) 53
Research & Development 54
Clinical Trials 56
Epidemiology 57
Table: Estimated Number Of New Cases Of Cancer In Singapore 58
Competitive Landscape 61
Research-Based Industry 61
Table: Multinational Pharmaceutical Firm Presence In Singapore 61
Table: Multinational Market Activity 62
Table: Leading Generic Drugmakers In Singapore 64
Pharmaceutical Distribution 65
Pharmaceutical Retail Sector 68
Company Profile 70
Baxter 70
GlaxoSmithKline 72
Haw Par 75
Merck & Co 78
MerLion 81
Novartis 84
Pfizer 87
Sanofi 90
Sci Gen 92
Demographic Forecast 95
Demographic Outlook 95
Table: Population Headline Indicators (Singapore 1990-2025) 96
Table: Key Population Ratios (Singapore 1990-2025) 96
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025) 97
Table: Population By Age Group (Singapore 1990-2025) 97
Table: Population By Age Group % (Singapore 1990-2025) 98
Glossary 100
Methodology 102
Pharmaceutical Expenditure Forecast Model 102
Healthcare Expenditure Forecast Model 102
Notes On Methodology 103
Risk/Reward Index Methodology 104
Index Overview 105
Table: Pharmaceutical Risk/Reward Index Indicators 105
Indicator Weightings 106

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Singapore 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Singapore 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Singapore 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Singapore 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Singapore 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Singapore 2014-2020)
Table: Regulatory Process Time Taken Under The CECA And Under The Abridged GDA
Table: Health Funding Sources In Singapore (SGDmn)
Table: Healthcare Resources (Singapore 2010-2015)
Table: Healthcare Activity (Singapore 2010-2015)
Table: Healthcare Personnel (Singapore 2010-2015)
Table: Estimated Number Of New Cases Of Cancer In Singapore
Table: Multinational Pharmaceutical Firm Presence In Singapore
Table: Multinational Market Activity
Table: Leading Generic Drugmakers In Singapore
Table: Population Headline Indicators (Singapore 1990-2025)
Table: Key Population Ratios (Singapore 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Singapore 1990-2025)
Table: Population By Age Group (Singapore 1990-2025)
Table: Population By Age Group % (Singapore 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators

Related Reports

  • Singapore Pharmaceuticals and Healthcare Report Q1 2016BMI View: Despite the small size of the Singaporean pharmaceutical market, the country's consistent drive into R&D, strong government commitment towards healthcare provision and its ageing population continue to present significant commercial opportunities for pharmaceutical firms. Furthermore, per capita pharmaceutical spending is high relative to the region which will be a strong plus for innovative drugmakers. Headline Expenditure Projections ? Pharmaceuticals: SGD1.04bn […]
  • Namibia Pharmaceuticals and Healthcare Report Q2 2016BMI View: The vast majority of Namibia's pharmaceutical needs will remain sourced from abroad, however, domestic production of ARV drug nevirapine shows a commitment to achieving self-sufficiency in terms of medicine production. However, this is unlikely to be achieved in the foreseeable future given the limited production capacity among domestic companies including Fabupharm. Headline Expenditure Forecasts ? Pharmaceuticals: NAD2.34bn (USD184mn) in 2015 to NAD2.56bn (USD172mn) in […]
  • Kuwait Pharmaceuticals and Healthcare Report Q3 2015BMI View: While the losses incurred by Yiaco, the largest drug distributor in Kuwait, highlight a deteriorated near-term operating environment, with markedly lower prices as a result of the ongoing Gulf Cooperation Council (GCC) medicine price unification process, drugmakers will continue to perceive high long-run returns. Exhibiting a high and very costly burden of diabetes and cardiovascular conditions, Kuwait's aging population will continue to receive rising access to quality […]
  • Switzerland Pharmaceuticals and Healthcare Report Q2 2016BMI View: Switzerland's epidemiological profile will continue to be attractive to manufacturers of medicines for non-communicable diseases. Despite the relative rapid uptake of innovative pharmaceuticals, the burden of chronic conditions will account for a large proportion of the total disease burden over the next 15 years. Like many other developed states, Switzerland is introducing cost-containment measures to restrict the commercial opportunities presented to drugmakers. Headline […]
  • Cambodia and Laos Pharmaceuticals and Healthcare Report Q4 2015BMI View: Commercial opportunities for drugmakers in Cambodia will remain limited despite the rising burden of both communicable and non-communicable diseases. Critically, the country's healthcare system remains underdeveloped, hindering access to pharmaceuticals and medical diagnosis. Moreover, revenue prospects for high value medicines remain limited due to the low purchasing power of the population and the dominance of out-of-pocket spending in healthcare financing. Headline […]